Citigroup
XFOR icon

Citigroup’s X4 Pharmaceuticals XFOR Stock Holding History

Citigroup’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$148K Buy
35,765
+3,433
+11% +$12.9K ﹤0.01% 4130
2025
Q4 		$129K Buy
32,332
+32,300
+100,938% +$117K ﹤0.01% 4202
2025
Q3 		$109 Sell
32
-730
-96% -$1.88K ﹤0.01% 5804
2025
Q2 		$1.45K Sell
762
-3,317
-81% -$13.6K ﹤0.01% 5382
2025
Q1 		$28.9K Sell
4,079
-495
-11% -$6.82K ﹤0.01% 5015
2024
Q4 		$101K Buy
4,574
+405
+10% +$6.46K ﹤0.01% 4838
2024
Q3 		$83.7K Buy
4,169
+2,950
+242% +$61.6K ﹤0.01% 4850
2024
Q2 		$21.2K Sell
1,219
-3,016
-71% -$98.6K ﹤0.01% 4984
2024
Q1 		$177K Buy
4,235
+3,647
+620% +$101K ﹤0.01% 4071
2023
Q4 		$14.8K Buy
588
+586
+29,300% +$14.3K ﹤0.01% 5085
2023
Q3 		$75 Sell
2
-1,220
-100% -$53.2K ﹤0.01% 5477
2023
Q2 		$71.1K Buy
+1,222
New +$62.8K ﹤0.01% 4422
2021
Q3 		– Sell
-1
Closed – – 6354
2021
Q2 		$0 Sell
1
-35
-97% -$8.8K ﹤0.01% 6438
2021
Q1 		$9K Sell
36
-65
-64% -$17.1K ﹤0.01% 5719
2020
Q4 		$19K Buy
101
+75
+288% +$14.7K ﹤0.01% 6700
2020
Q3 		$5K Sell
26
-44
-63% -$10.5K ﹤0.01% 7053
2020
Q2 		$20K Sell
70
-35
-33% -$9.58K ﹤0.01% 6630
2020
Q1 		$31K Buy
105
+26
+33% +$7.38K ﹤0.01% 6388
2019
Q4 		$25K Buy
79
+59
+295% +$21.2K ﹤0.01% 6824
2019
Q3 		$7K Sell
20
-45
-69% -$17.8K ﹤0.01% 7232
2019
Q2 		$29K Buy
65
+52
+400% +$26.4K ﹤0.01% 6897
2019
Q1 		$6K Buy
13
+5
+63% +$2.76K ﹤0.01% 7394
2018
Q4 		$3K Sell
8
-694
-99% -$265K ﹤0.01% 7471
2018
Q3 		$205K Buy
702
+698
+17,450% +$296K ﹤0.01% 5231
2018
Q2 		$2K Buy
4
+1
+33% +$3.27K ﹤0.01% 7479
2018
Q1 		$14K Sell
3
-1
-25% -$2.91K ﹤0.01% 6923
2017
Q4 		$9K Buy
+4
New +$10.1K ﹤0.01% 7084

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citigroup's XFOR Position: Q1 2026 in Review

Citigroup increased its X4 Pharmaceuticals (XFOR) stake by 11% in Q1 2026, buying an estimated $12.9K and bringing the position to 35,765 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #4130.

Citigroup first reported a position in XFOR in Q4 2017 and has held it in 27 quarters since. The position peaked at $205K in Q3 2018. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Citigroup held 35,765 shares of X4 Pharmaceuticals worth $148K as of Q1 2026.
  • Citigroup bought 3,433 X4 Pharmaceuticals shares in Q1 2026, an estimated $12.9K.
  • X4 Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4130 holding.
  • Citigroup first reported a position in X4 Pharmaceuticals in Q4 2017 and has held it in 27 quarters since.
  • Citigroup's X4 Pharmaceuticals position peaked at $205K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.